ホーム › 非小細胞肺癌 › ペンシルベニア

ペンシルベニアにおける非小細胞肺癌の臨床試験

ペンシルベニア内の拠点で、非小細胞肺癌に関する103件の研究が参加者を募集しています。

ペンシルベニア内の都市

公式研究テキスト（英語）

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Lehigh Valley Hospital-Cedar Crest, Allentown
UPMC Altoona, Altoona
UPMC-Heritage Valley Health System Beaver, Beaver
他53件

被験者募集中第3相

18歳以上 · 全性別 · 2026/10/02更新 · NCT04267848

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

St. Lukes Hospital and Health Network ( Site 0186), Bethlehem

被験者募集中第3相

18歳以上 · 全性別 · 2026/10/02更新 · NCT06623422

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

UPMC-Heritage Valley Health System Beaver, Beaver
Carlisle Regional Cancer Center, Carlisle
UPMC Hillman Cancer Center Erie, Erie
他17件

被験者募集中第2相

18歳以上 · 全性別 · 2026/10/02更新 · NCT07293247

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Abramson Cancer Center of the University of Pennsylvania, Philadelphia
University of Pittsburgh Medical Center, Pittsburgh
WellSpan York Cancer Center, York

被験者募集中第1/2相

12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #104, Hershey
Exelixis Clinical Site #98, Philadelphia
Exelixis Clinical Site #32, Pittsburgh

被験者募集中第1相

18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

AHN Cancer Institute - Allegheny General ( Site 9501), Pittsburgh

被験者募集中第2相

18歳以上 · 全性別 · 2026/10/01更新 · NCT06780085

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Perelman Center for Advanced Medicine ( Site 3205), Philadelphia

被験者募集中第3相

18歳以上 · 全性別 · 2026/10/01更新 · NCT07513376

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0111), Lancaster

被験者募集中第3相

18歳以上 · 全性別 · 2026/10/01更新 · NCT07190248

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Lehigh Valley Hospital-Cedar Crest, Allentown
Lehigh Valley Hospital - Muhlenberg, Bethlehem
Bryn Mawr Hospital, Bryn Mawr
他14件

被験者募集中第3相

18歳以上 · 全性別 · 2026/10/01更新 · NCT06498635

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Lancaster General Hospital, Lancaster
Local Institution - 0028, Pittsburgh
WellSpan Oncology Research, York

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/30更新 · NCT07361510

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Alliance Cancer Specialists, Sellersville

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/30更新 · NCT06765109

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Research Site, Pittsburgh

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/29更新 · NCT05877599

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Spoknwrd Clinical Trials /ID# 273776, Easton

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/29更新 · NCT06772623

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Penn State Milton S. Hershey Medical Center, Hershey

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/29更新 · NCT06881784

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Alliance Cancer Specialists, PC, Bensalem
Consultants in Medical Oncology and Hematology, P.C., Broomall
Alliance Cancer Specialists, PC, Doylestown
他5件

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/28更新 · NCT07144280

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Penn State Milton S. Hershey Medical Center-Penn State Cancer Institute ( Site 0059), Hershey
Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0068), Lancaster

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/25更新 · NCT06312137

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Alliance Cancer Specialists - Media, Media
Guthrie Medical Group, Sayre

被験者募集中第3相

18歳〜100歳 · 全性別 · 2026/09/25更新 · NCT05920356

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Research Site, Philadelphia
Research Site, Pittsburgh

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/25更新 · NCT06218914

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Thomas Jefferson University Hospital, Philadelphia
Jefferson Health Northeast, Philadelphia
McGlinn Cancer Institute Reading Hospital, West Reading

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/25更新 · NCT06667076

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

University of Pennsylvania, Philadelphia

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/25更新 · NCT06667908

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Research Site, Fountain Hill
Research Site, Kittanning
Research Site, Philadelphia

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/25更新 · NCT06868277

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
Jefferson Hospital Northeast, Philadelphia
AHN Allegheny General Hospital, Pittsburgh

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/24更新 · NCT06890598